Amicus price target raised to $19 from $16 at BofA

BofA raised the firm’s price target on Amicus to $19 from $16 and keeps a Buy rating on the shares after the FDA approved Pombiliti + Opfolda for the treatment of LOPD patients who are not improving on their current ERT therapy. Management highlighted the label is in-line with their expectations and announced they expect the list price of P+O to be about $650,000 per year for a patient weighing 70 kg, says the analyst, who is “encouraged” by the approval in the U.S. following the recent approval in the EU.